Sarah Sammons

Assistant Professor

Dana-Farber Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States Professors in Medical Imaging Medical Imaging professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sarah Sammons is an Assistant Professor at the Dana-Farber Cancer Institute in the United States. Her research primarily focuses on breast cancer, particularly the management of brain metastases, treatment strategies for advanced breast cancer, and the implications of specific genetic mutations in patient outcomes. She has published several articles addressing recent advancements in therapies and the complexities faced by patients with hormone receptor-positive and HER2-negative breast cancer.

Articles (11)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Kevin Kalinsky

Emory University

UNITED STATES

View details

KYONG HWA PARK

Associate Professor

Seoul National University Hospital

SOUTH KOREA

View details

Laura Alder

Duke University

UNITED STATES

View details

Sheheryar Kabraji

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES

View details

Giampaolo Bianchini

Head Breast Cancer Group

IRCCS Ospedale San Raffaele

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sarah Sammons

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial

Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer

Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study)

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases

Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer

APOBEC Mutational Signatures in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy

Advances in the management of breast cancer brain metastases

The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part I: Early-Stage Disease

The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part II: Metastatic Disease

Collaborators (5)

Kevin Kalinsky

KYONG HWA PARK

Laura Alder

Sheheryar Kabraji

Giampaolo Bianchini

Make your next move.